BIVI: Bezisterim showed no overall statistical benefit in Long COVID, but subgroup signals warrant further study
The Phase 2 ADDRESS-LC trial of bezisterim in Long COVID did not achieve statistical significance in the overall population, though some pre-specified subgroups showed promising signals. Further studies are planned to clarify efficacy and inform Phase 3 design.Original document: BioVie Inc. [BIVI…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.